News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
US FDA Staff Backs CSL Behring Clot Disorder Therapy
January 7, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
WASHINGTON, Jan 7 (Reuters) - CSL Ltd's proposed treatment for a rare bleeding disorder appears safe and effective enough to support approval, U.S. drug reviewers said in documents released on Wednesday.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Food and Drug Administration (FDA)
CSL
MORE ON THIS TOPIC
Podcast
Unpacking the Latest MAHA Report, RFK’s Senate Appearance, FDA’s CRL Drop and More
September 10, 2025
·
1 min read
·
Jef Akst
Government
Second MAHA Report Emphasizes Chronic Disease, Tilts at Vaccine Reform
September 9, 2025
·
3 min read
·
Heather McKenzie
Complete response letters
FDA Turns Away Ultra-Rare Disease Therapy
September 9, 2025
·
2 min read
·
Tristan Manalac
FDA
FDA Demurs on GLP-1 Compounding Fight, Debuts Consumer ‘Green List’ Instead
September 8, 2025
·
2 min read
·
Annalee Armstrong
